141 Therapeutic potential of targeting drug in pemphigus

Pemphigus is a heterogeneous group of autoimmune skin disorders characterized by blistering the and mucosal membranes, potentially affecting quality life if left unchecked. The current mainstay treatment systemic corticosteroids immunosuppressive agents. Nevertheless, long-term use these drugs can easily cause infections other life-threatening adverse reactions. Therefore, many targeted therapies have been gradually introduced used for pemphigus. Among therapies, rituximab has approved as first-line moderate to severe cases pemphigus vulgaris (PV) in some countries. With an increasing number are being tested clinical trials, this study, we review research progress on mechanism